Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

BeiGene

Will Trump’s drug order derail China’s overseas pharma push?

Will Trump’s drug order put the brakes on China’s overseas pharma drive?

The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
May 22, 2025
BeiGene celebrates profit milestone

BeiGene celebrates profit milestone on soaring drug sales

Buoyed by U.S. demand for its blockbuster cancer drug, the Chinese biopharma firm has delivered its first quarterly profit on a GAAP basis Key Takeaways: Global sales of the company’s…
May 15, 2025
6160.HK ONC.US 688325.SHG
Earnings blow for CSPC Pharma

Earnings blow for CSPC Pharma as the state drives a hard bargain

The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines   Key Takeaways: CSPC Pharma…
March 6, 2025
1093.HK
BeiGene

BeiGene heads for profit milestone after hemorrhaging cash

With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
January 24, 2025
6160.HK ONC.US 688235.SHG
The biopharmaceutical company had planned to sell a 20% stake in its international unit to the group’s founder, but the cheap price sparked a crisis of market confidence.

Innovent ditches low-value stake sale after investor outcry

The biopharmaceutical company had planned to sell a 20% stake in its international unit to the group’s founder, but the cheap price sparked a crisis of market confidence Key Takeaways:…
November 7, 2024
1801.HK

BRIEF: BeiGene executive reportedly detained in AstraZeneca investigation

Yin Min, chief business officer for Greater China at innovative drugmaker BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH), has been detained as part of an investigation unrelated to the company’s operations, according…
October 28, 2024
BGNE.US 6160.HK
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum lags the pace of leading rivals.

Junshi narrows its losses but delivers no cure for share price woes

The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
September 12, 2024
1877.HK 688180.SHG
Load more

Recent Articles

Will Trump’s drug order derail China’s overseas pharma push?
May 22, 2025

Will Trump’s drug order put the brakes on China’s overseas pharma drive?

May 15, 2025

BeiGene celebrates profit milestone on soaring drug sales

6160.HK ONC.US 688325.SHG
March 6, 2025

Earnings blow for CSPC Pharma as the state drives a hard bargain

1093.HK
January 24, 2025

BeiGene heads for profit milestone after hemorrhaging cash

6160.HK ONC.US 688235.SHG
November 7, 2024

Innovent ditches low-value stake sale after investor outcry

1801.HK
October 28, 2024

BRIEF: BeiGene executive reportedly detained in AstraZeneca investigation

BGNE.US 6160.HK
September 12, 2024

Junshi narrows its losses but delivers no cure for share price woes

1877.HK 688180.SHG

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  3. January 21, 2025
    What’s Ahead for China Inc. Under Trump 2.0?
  4. December 13, 2024
    Innogen Pharma jostles for a slice of the weight-loss market
  5. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  6. April 17, 2025
    WuXi group wrestles with uncertainty over pharma tariffs
    2268.HK
  7. March 13, 2025
    No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.